Charles Bishop Email Address

Chief Executive Officer, Renal Division

OPKO Health, Inc. (OPKO) is a healthcare company. The Company operates through two segments: diagnostics and pharmaceutical. The pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, and its pharmaceutical research and development operations. The diagnostics segment primarily consists of its clinical laboratory operations. The Company's diagnostics business includes Bio-Reference Laboratories (Bio-Reference), which is a clinical laboratory with a genetic testing business, including the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform. Its pharmaceutical business includes OPKO Biologics, which features hGH-CTP, a once-weekly human growth hormone injection (in Phase III and partnered with Pfizer), and a longer acting Factor VIIa drug for hemophilia (Phase IIa). In addition to its pharmaceutical and diagnostic development programs, it owns pharmaceutical platforms in Ireland, Chile, Spain and Mexico.

Dr. Bishop assumed his present position as CEO, Renal Division of OPKO Health when OPKO Health (NYSE:OPK) acquired Cytochroma Inc. and Proventiv Therapeutics on March 4, 2013. He had served as President & CEO of Cytochroma since June 2006 and Proventiv Therapeutics, a company which he co-founded, since September 2005. Proventiv Therapeutics was acquired by Cytochroma Holdings ULC in June 2006. During the period of September 1987 to June 2005, Dr. Bishop held various senior management positions at Bone Care International, a public specialty pharmaceutical company (NASDAQ: BCII) focused on developing and commercializing vitamin D hormone therapies. Dr. Bishop's positions within Bone Care included President, CEO, Director, Executive Vice President of Research & Development, and Chief Scientific Officer. Under Dr. Bishop's direction, Bone Care advanced a portfolio of proprietary vitamin D hormones and analogs to varying stages of development for the indication of secondary hyperparathyroidism (SHPT), metabolic bone disease, psoriasis and cancers of the prostate, breast and colon. Dr. Bishop was responsible for the successful preparation and prosecution of three New Drug Applications (NDAs) that ultimately led to FDA approval of a novel vitamin D drug, named doxercalciferol, for SHPT in dialysis patients (Hectorol 2.5 mcg Capsules and Hectorol Injection) and pre-dialysis patients (Hectorol 0.5 mcg Capsules). Hectorol is now the most widely used vitamin D hormone replacement therapy in the United States. Prior to joining Bone Care, Dr. Bishop held various management positions in the Health Care Division of the Procter & Gamble Company. Dr. Bishop completed a four-year National Institutes of Health Postdoctoral Fellowship in vitamin D biochemistry at the University of Wisconsin-Madison and received his PhD degree in Nutritional Biochemistry from Virginia Tech, after completing a BA in Chemistry at the University of Virginia.